Exploratory Cost-Effectiveness Analysis for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: Is Linezolid or Daptomycin Favored Over Vancomycin?-Reference-Cited by-同舟云学术

Exploratory Cost-Effectiveness Analysis for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: Is Linezolid or Daptomycin Favored Over Vancomycin?

Published:2021-09-04 Issue:10 Volume:41 Page:885-894
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Vu Michelle,Smith Kenneth J.,Aspinall Sherrie L.,Clancy Cornelius J.,Buehrle Deanna J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-021-01077-8.pdf

Reference42 articles.

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55.

2. Gould IM, Reilly J, Bunyan D, Walker A. Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control. Clin Microbiol Infect. 2010;16:1721–8.

3. Jeffres MN. The whole price of vancomycin: toxicities, troughs, and time. Drugs. 2017;77:1143–54.

4. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57:734–44.

5. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med Boston. 2006;355:653–65.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Treatment Outcomes of Infants and Children Treated With Daptomycin: Six-Year Experience From a Pediatric Academic Medical Center;Clinical Pediatrics;2024-03-30

2. Time for a Change: Considering Vancomycin Alternatives for Pediatric Methicillin-Resistant Staphylococcus aureus Bacteremia;Journal of the Pediatric Infectious Diseases Society;2023-05-01

3. An Update on Treatment Options for Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: A Systematic Review;Cureus;2022-11-14

4. Daptomycin likely cost effective compared with other regimens for MRSA blood infections in the USA;PharmacoEconomics & Outcomes News;2021-09